BACKGROUND: There are concerns about highly active antiretroviral therapy (HAART) causing a progressive increase in the risk of ischemic heart disease. We examined this issue in a nationwide cohort study of patients with human immunodeficiency virus (HIV) infection and a population-based control group. METHODS: We determined the rate of first hospitalization for ischemic heart disease in all Danish patients with HIV infection (3953 patients) from 1 January 1995 through 31 December 2004 and compared this rate with that for 373,856 subjects in a population-based control group. Data on first hospitalization for ischemic heart disease and comorbidity were obtained from the Danish National Hospital Registry for all study participants. We used Cox's regression to compute the hospitalization rate ratio as an estimate of relative risk, adjusting for comorbidity. RESULTS: Although the difference was not statistically significant, patients with HIV infection who had not initiated HAART were slightly more likely to be hospitalized for the first time with ischemic heart disease than were control subjects (adjusted relative risk, 1.39; 95% confidence interval, 0.81-2.33). After HAART initiation, the risk increase became substantially higher (adjusted relative risk, 2.12; 95% confidence interval, 1.62-2.76), but the relative risk did not further increase in the initial 8 years of HAART. CONCLUSIONS: Compared with the general population, HIV-infected patients receiving HAART have an increased risk of ischemic heart disease, but the relative risk is stable up to 8 years after treatment initiation.
BACKGROUND: There are concerns about highly active antiretroviral therapy (HAART) causing a progressive increase in the risk of ischemic heart disease. We examined this issue in a nationwide cohort study of patients with human immunodeficiency virus (HIV) infection and a population-based control group. METHODS: We determined the rate of first hospitalization for ischemic heart disease in all Danish patients with HIV infection (3953 patients) from 1 January 1995 through 31 December 2004 and compared this rate with that for 373,856 subjects in a population-based control group. Data on first hospitalization for ischemic heart disease and comorbidity were obtained from the Danish National Hospital Registry for all study participants. We used Cox's regression to compute the hospitalization rate ratio as an estimate of relative risk, adjusting for comorbidity. RESULTS: Although the difference was not statistically significant, patients with HIV infection who had not initiated HAART were slightly more likely to be hospitalized for the first time with ischemic heart disease than were control subjects (adjusted relative risk, 1.39; 95% confidence interval, 0.81-2.33). After HAART initiation, the risk increase became substantially higher (adjusted relative risk, 2.12; 95% confidence interval, 1.62-2.76), but the relative risk did not further increase in the initial 8 years of HAART. CONCLUSIONS: Compared with the general population, HIV-infectedpatients receiving HAART have an increased risk of ischemic heart disease, but the relative risk is stable up to 8 years after treatment initiation.
Authors: Matthew S Freiberg; Chung-Chou H Chang; Lewis H Kuller; Melissa Skanderson; Elliott Lowy; Kevin L Kraemer; Adeel A Butt; Matthew Bidwell Goetz; David Leaf; Kris Ann Oursler; David Rimland; Maria Rodriguez Barradas; Sheldon Brown; Cynthia Gibert; Kathy McGinnis; Kristina Crothers; Jason Sico; Heidi Crane; Alberta Warner; Stephen Gottlieb; John Gottdiener; Russell P Tracy; Matthew Budoff; Courtney Watson; Kaku A Armah; Donna Doebler; Kendall Bryant; Amy C Justice Journal: JAMA Intern Med Date: 2013-04-22 Impact factor: 21.873
Authors: Margalida Rotger; Tracy R Glass; Thomas Junier; Jens Lundgren; James D Neaton; Estella S Poloni; Angélique B van 't Wout; Rubin Lubomirov; Sara Colombo; Raquel Martinez; Andri Rauch; Huldrych F Günthard; Jacqueline Neuhaus; Deborah Wentworth; Danielle van Manen; Luuk A Gras; Hanneke Schuitemaker; Laura Albini; Carlo Torti; Lisa P Jacobson; Xiuhong Li; Lawrence A Kingsley; Federica Carli; Giovanni Guaraldi; Emily S Ford; Irini Sereti; Colleen Hadigan; Esteban Martinez; Mireia Arnedo; Lander Egaña-Gorroño; Jose M Gatell; Matthew Law; Courtney Bendall; Kathy Petoumenos; Jürgen Rockstroh; Jan-Christian Wasmuth; Kabeya Kabamba; Marc Delforge; Stephane De Wit; Florian Berger; Stefan Mauss; Mariana de Paz Sierra; Marcelo Losso; Waldo H Belloso; Maria Leyes; Antoni Campins; Annalisa Mondi; Andrea De Luca; Ignacio Bernardino; Mónica Barriuso-Iglesias; Ana Torrecilla-Rodriguez; Juan Gonzalez-Garcia; José R Arribas; Iuri Fanti; Silvia Gel; Jordi Puig; Eugenia Negredo; Mar Gutierrez; Pere Domingo; Julia Fischer; Gerd Fätkenheuer; Carlos Alonso-Villaverde; Alan Macken; James Woo; Tara McGinty; Patrick Mallon; Alexandra Mangili; Sally Skinner; Christine A Wanke; Peter Reiss; Rainer Weber; Heiner C Bucher; Jacques Fellay; Amalio Telenti; Philip E Tarr Journal: Clin Infect Dis Date: 2013-03-26 Impact factor: 9.079
Authors: Daniel A Duprez; Lewis H Kuller; Russell Tracy; James Otvos; David A Cooper; Jennifer Hoy; Jacqueline Neuhaus; Nicholas I Paton; Nina Friis-Moller; Fiona Lampe; Angelike P Liappis; James D Neaton Journal: Atherosclerosis Date: 2009-05-13 Impact factor: 5.162